Targeting the Epidermal Growth Factor Receptor in Non-small-cell Lung Cancer: Who, Which, When, and How?

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2007 Jun 26

PMID 17588349

Citations 8

Authors

Rosalyn Juergens

Julie Brahmer

Affiliations

Soon will be listed here.

Abstract

Aberrations in the signaling cascade of the epidermal growth factor receptor are common to several solid tumors. Compounds aimed at targeting this pathway have been approved for use by the US Food and Drug Administration for lung, head and neck, pancreas, and colorectal carcinomas. Unfortunately, only the minority of patients treated with this class of agents will have responses or improvements in survival. This article reviews the data on agents that exploit tumor dependency on epidermal growth factor receptor cascade and describes the knowledge on how to discern the appropriate patient population for receiving these agents.

Citing Articles

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N Clin Transl Oncol. 2018; 21(6):721-728.

PMID: 30374838 DOI: 10.1007/s12094-018-1968-3.

miR-1290 is a potential prognostic biomarker in non-small cell lung cancer.

Mo D, Gu B, Gong X, Wu L, Wang H, Jiang Y J Thorac Dis. 2015; 7(9):1570-9.

PMID: 26543604 PMC: 4598517. DOI: 10.3978/j.issn.2072-1439.2015.09.38.

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.

Li J, Deng H, Hu M, Fang Y, Vaughn A, Cai X Oncotarget. 2015; 6(9):6749-61.

PMID: 25730907 PMC: 4466647. DOI: 10.18632/oncotarget.3155.

Transcription factor glioma-associated oncogene homolog 1 is required for transforming growth factor-β1-induced epithelial-mesenchymal transition of non-small cell lung cancer cells.

Li H, Da L, Fan W, Long X, Zhang X Mol Med Rep. 2015; 11(5):3259-68.

PMID: 25586417 PMC: 4368139. DOI: 10.3892/mmr.2015.3150.

Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells.

Chen X, Xie X, Zhao Q, Wang F, Bai Y, Yin J Mol Med Rep. 2014; 11(1):105-12.

PMID: 25333250 PMC: 4237074. DOI: 10.3892/mmr.2014.2733.

References

Lin W, Chiu C, Liou J, Chen Y, Perng R, Tsai C . Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer. 2006; 54(2):193-9. DOI: 10.1016/j.lungcan.2006.07.013. View

West H, Franklin W, McCoy J, Gumerlock P, Vance R, Lau D . Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006; 24(12):1807-13. DOI: 10.1200/JCO.2005.04.9890. View

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

Mendelsohn J, Baselga J . The EGF receptor family as targets for cancer therapy. Oncogene. 2001; 19(56):6550-65. DOI: 10.1038/sj.onc.1204082. View

Robert F, Blumenschein G, Herbst R, Fossella F, Tseng J, Saleh M . Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(36):9089-96. DOI: 10.1200/JCO.2004.00.1438. View

Ranson M, Hammond L, Ferry D, Kris M, Tullo A, Murray P . ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002; 20(9):2240-50. DOI: 10.1200/JCO.2002.10.112. View

Dziadziuszko R, Holm B, Skov B, Osterlind K, Sellers M, Franklin W . Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2006; 18(3):447-52. DOI: 10.1093/annonc/mdl407. View

Hirsch F, Varella-Garcia M, Bunn Jr P, Franklin W, Dziadziuszko R, Thatcher N . Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24(31):5034-42. DOI: 10.1200/JCO.2006.06.3958. View

10.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

11.

Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16):2149-58. DOI: 10.1001/jama.290.16.2149. View

12.

Thomas L, Doyle L, Edelman M . Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005; 128(1):370-81. DOI: 10.1378/chest.128.1.370. View

13.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D . Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20(21):4292-302. DOI: 10.1200/JCO.2002.03.100. View

14.

Jensen A, Munter M, Bischoff H, Haselmann R, Timke C, Krempien R . Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer. 2006; 6:122. PMC: 1524801. DOI: 10.1186/1471-2407-6-122. View

15.

Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F . HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007; 19(1):56-62. DOI: 10.1097/GCO.0b013e328012980a. View

16.

Hirsch F, Varella-Garcia M, Bunn Jr P, Di Maria M, Veve R, Bremmes R . Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21(20):3798-807. DOI: 10.1200/JCO.2003.11.069. View

17.

Herbst R, Johnson D, Mininberg E, Carbone D, Henderson T, Kim E . Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell.... J Clin Oncol. 2005; 23(11):2544-55. DOI: 10.1200/JCO.2005.02.477. View

18.

Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J . Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005; 353(2):133-44. DOI: 10.1056/NEJMoa050736. View

19.

Hanna N, Shepherd F, Fossella F, Pereira J, de Marinis F, von Pawel J . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22(9):1589-97. DOI: 10.1200/JCO.2004.08.163. View

20.

Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, ORourke M . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18(10):2095-103. DOI: 10.1200/JCO.2000.18.10.2095. View